We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be th... Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition. Show more
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire BOSTON, Sept. 3, 2024 BOSTON, Sept. 3, 2024 /PRNewswire/ --Β Elevation Oncology, Inc...
Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements PR Newswire BOSTON, Aug. 6, 2024 -- Today announced promising initial data from Phase...
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin...
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer PR Newswire BOSTON, June 27, 2024 -- Plan to evaluate EO-3021 in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.108 | -14.8351648352 | 0.728 | 0.8358 | 0.595 | 658705 | 0.72443563 | CS |
4 | -2.13 | -77.4545454545 | 2.75 | 3.28 | 0.595 | 1265288 | 1.40746075 | CS |
12 | -3.46 | -84.8039215686 | 4.08 | 5.8299 | 0.595 | 939274 | 2.48193611 | CS |
26 | -0.09 | -12.676056338 | 0.71 | 5.8299 | 0.363 | 1267992 | 2.34145324 | CS |
52 | -9.82 | -94.061302682 | 10.44 | 10.97 | 0.363 | 717239 | 2.77497701 | CS |
156 | -13.38 | -95.5714285714 | 14 | 16.22 | 0.363 | 675623 | 2.85763726 | CS |
260 | 0 | 0 | 0 | 0.668299 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions